Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3265024, 7 pages
Clinical Study

Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Correspondence should be addressed to Wei Xu; moc.qq@5519463042

Received 19 August 2017; Accepted 19 October 2017; Published 9 November 2017

Academic Editor: Fabio Sonvico

Copyright © 2017 Yan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of the study was to investigate the efficacy and safety of halometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol (COR) levels. Sixty consecutive outpatients diagnosed with chronic generalized eczema between January and April 2017 were included and divided into groups A, B, and C with a lesion area of 30%–40%, 41%–50%, and 51%–60%, respectively. Groups A, B, and C were treated with halometasone cream with a daily dose of 15 g, 20 g, and 30 g for 7–14 days, respectively. Ten patients were randomly selected from each group for serum COR measurement at days 0, 7, and 14. On day 14, group B had significantly higher cure rate (47.1%) than groups A (17.9%) and C (13.3%) and significantly higher effectiveness rate (82.4%) than group C (40.0%) (all ). Serum COR levels were not affected in group A but were reduced significantly in groups B and C on days 7 and 14 (all ). No adverse reaction was observed. Halometasone cream appeared to relieve chronic generalized eczema effectively and safely. High dosage (≥20 g daily for 14 days) may temporarily reduce endogenous COR production substantially, although it may be more effective.